Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2561 | Nitric Oxide delivered via LungFit™ system Wiki | 1.00 |
| drug2916 | Placebo Wiki | 0.04 |
Navigate: Correlations HPO
There is one clinical trial.
A phase 2, placebo-controlled study of the safety and efficacy of STI-5656 (Abivertinib Maleate) in subjects hospitalized due to COVID-19
Description: Proportion of subjects whoa re alive and discharged from the hospital by Day 29
Measure: Proportion of subjects discharged from hospital Time: Randomization through Day 29Description: Types, frequencies, and severities of adverse events and their relationships to STI-5656, including serious adverse events
Measure: Incidence of adverse events (safety) Time: Randomization through study completion through Day 36Description: Time from onset of COVID-19 symptoms to hospital admission, time from hospitalization to start of treatment (D1), and time from D1 to hospital discharge
Measure: Time to hospital admission, treatment, and discharge Time: Randomization through study completion through Day 36Description: Number of days hospitalized from randomization through Day 36
Measure: Number of days hospitalized Time: Randomization to Day 36Description: Change in clinical status as assessed using a 0-8 ordinal scale, where a lower score equals better outcome, at Days 3, 10, and 36
Measure: Change in clinical status as assessed using a 0-8 ordinal scale Time: Randomization to Day 3, Day 10, and Day 36Description: Change in RT-PCR test results (or equivalent) at Days 3, 10, and 36
Measure: Change in RT-PCR test results Time: Randomization to Day 3, Day 10, and Day 36Description: Change in C-reactive protein (CRP) levels at Day 3 and Day 10
Measure: Change in C-reactive protein levels Time: Randomization to Day 3 and Day 10Description: Area under the serum concentration-time curve (AUC) of STI-5656
Measure: AUC of STI-5656 (PK) Time: Randomization through Day 8Description: Maximum observed serum concentration (Cmax) of STI-5656
Measure: Cmax of STI-5656 (PK) Time: Randomization through Day 8Description: Apparent serum terminal elimination half life (t½) of STI-5656
Measure: t½ of STI-5656 (PK) Time: Randomization through Day 8Description: Change in cytokine levels (including IL-6, TNF-a, IFNγ, IL1β) at Day 3 and Day 10
Measure: Change in cytokine levels Time: Randomization to Day 3 and Day 10Description: Time to Cmax (Tmax) of STI-5656
Measure: Tmax of STI-5656 (PK) Time: Randomization through Day 8Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports